Q3 Data Growth Accelerates but Cash Returns Lag

What happened

Tempus reported Q3 2026 results showing Diagnostics revenue growth of 20% and Data & Applications growth of 33%, indicating continued platform momentum. Adjusted EBITDA improved, but GAAP losses persisted, highlighting the gap between operational progress and bottom-line profitability. The Data & Applications segment's 33% growth is above the 28% threshold that would trigger an upgrade per our prior framework, but conversion quality and contract opt-out clauses remain a concern. The company's cash generation has not caught up, with persistent GAAP losses and the pending $1.5B Personalis acquisition still to be integrated. Overall, the results reinforce the platform thesis but do not yet resolve the margin and cash return concerns.

Implication

The upgrade threshold for Data & Applications growth (above 28%) has been met for Q3, but the other condition—Personalis included with unchanged EBITDA guidance—has not been confirmed. Until Tempus provides clarity on the acquisition's impact on margins and funding, the WAIT rating remains appropriate. The persistent GAAP losses despite improving adjusted EBITDA suggest that stock-based compensation and fair-value adjustments continue to obscure true profitability. Cash returns are still insufficient, and the market's valuation appears to price in significant future success. Investors should watch for evidence of MRD revenue and reimbursement progress and any changes to EBITDA guidance post-Personalis.

Thesis delta

The thesis shifts only slightly: Data & Applications growth at 33% is stronger than the 28% upgrade trigger, but the key condition of Personalis inclusion with unchanged EBITDA guidance is still unresolved. The overall WAIT rating is unchanged because GAAP losses and cash generation concerns persist. The upcoming Personalis closing and next earnings commentary will be critical in determining whether the upgrade criteria are fully met.